Search: onr:"swepub:oai:lup.lub.lu.se:d28df80f-9433-4f99-98e7-bd5b425390d9" > Methotrexate, Doxor...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05703naa a2200889 4500 | |
001 | oai:lup.lub.lu.se:d28df80f-9433-4f99-98e7-bd5b425390d9 | |
003 | SwePub | |
008 | 160401s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/75085152 URI |
024 | 7 | a https://doi.org/10.1200/JCO.2014.60.07342 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Bielack, Stefan S4 aut |
245 | 1 0 | a Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial |
264 | 1 | c 2015 |
338 | a electronic2 rdacarrier | |
520 | a Purpose EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients and Methods At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). Results Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. Conclusion At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Smeland, Sigbjørn4 aut |
700 | 1 | a Whelan, Jeremy S4 aut |
700 | 1 | a Marina, Neyssa4 aut |
700 | 1 | a Jovic, Gordana4 aut |
700 | 1 | a Hook, Jane M4 aut |
700 | 1 | a Krailo, Mark D4 aut |
700 | 1 | a Gebhardt, Mark4 aut |
700 | 1 | a Pápai, Zsuzsanna4 aut |
700 | 1 | a Meyer, James4 aut |
700 | 1 | a Nadel, Helen4 aut |
700 | 1 | a Randall, R Lor4 aut |
700 | 1 | a Deffenbaugh, Claudia4 aut |
700 | 1 | a Nagarajan, Rajaram4 aut |
700 | 1 | a Brennan, Bernadette4 aut |
700 | 1 | a Letson, G Douglas4 aut |
700 | 1 | a Teot, Lisa A4 aut |
700 | 1 | a Goorin, Allen4 aut |
700 | 1 | a Baumhoer, Daniel4 aut |
700 | 1 | a Kager, Leo4 aut |
700 | 1 | a Werner, Mathias4 aut |
700 | 1 | a Lau, Ching C4 aut |
700 | 1 | a Sundby Hall, Kirsten4 aut |
700 | 1 | a Gelderblom, Hans4 aut |
700 | 1 | a Meyers, Paul4 aut |
700 | 1 | a Gorlick, Richard4 aut |
700 | 1 | a Windhager, Reinhard4 aut |
700 | 1 | a Helmke, Knut4 aut |
700 | 1 | a Eriksson, Mikaelu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mer |
700 | 1 | a Hoogerbrugge, Peter M4 aut |
700 | 1 | a Schomberg, Paula4 aut |
700 | 1 | a Tunn, Per-Ulf4 aut |
700 | 1 | a Kühne, Thomas4 aut |
700 | 1 | a Jürgens, Heribert4 aut |
700 | 1 | a van den Berg, Henk4 aut |
700 | 1 | a Böhling, Tom4 aut |
700 | 1 | a Picton, Susan4 aut |
700 | 1 | a Renard, Marleen4 aut |
700 | 1 | a Reichardt, Peter4 aut |
700 | 1 | a Gerss, Joachim4 aut |
700 | 1 | a Butterfass-Bahloul, Trude4 aut |
700 | 1 | a Morris, Carol4 aut |
700 | 1 | a Hogendoorn, Pancras C W4 aut |
700 | 1 | a Seddon, Beatrice4 aut |
700 | 1 | a Calaminus, Gabriele4 aut |
700 | 1 | a Michelagnoli, Maria4 aut |
700 | 1 | a Dhooge, Catharina4 aut |
700 | 1 | a Sydes, Matthew R4 aut |
700 | 1 | a Bernstein, Mark4 aut |
710 | 2 | a Tumörmikromiljöb Sektion I4 org |
773 | 0 | t Journal of Clinical Oncologyg 33:20, s. 2279-2287q 33:20<2279-2287x 1527-7755 |
856 | 4 | u https://portal.research.lu.se/files/1692560/8560306x primaryx freey FULLTEXT |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/26033801?dopt=Abstractx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1200/JCO.2014.60.0734x freey FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/7508515 |
856 | 4 8 | u https://doi.org/10.1200/JCO.2014.60.0734 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.